Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07412704
Recruiting Phase 1/2

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

NCT07412704 · tracked via the Priya Life Science USA tracker
Sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Started
2026-10-06
Last updated
2026-10-23

Condition(s) studied

Arthritis, Rheumatoid

Investigational drug(s) / intervention(s)

BMS-986528

BMS-986528: Specified dose on specified days

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria \- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat. Exclusion Criteria * Juvenile arthritis or onset of inflammatory arthritis before age 18. * Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out. * Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment. * Other protocol-defined Inclusion/Exclusion criteria apply.

Primary outcome measure(s)

  • Number of participants with treatment-emergent adverse events (TEAEs) — Up to Week 54
  • Number of participants with Serious Adverse Events (SAEs) — Up to Week 54

Trial sites (39)

FacilityCityRegionStatus
Local Institution - 0068 La Jolla California Not Yet Recruiting
Local Institution - 0070 Loma Linda California Not Yet Recruiting
Local Institution - 0069 Palo Alto California Not Yet Recruiting
Local Institution - 0050 Aurora Colorado Not Yet Recruiting
Colorado Blood Cancer Institute Denver Colorado Recruiting
Local Institution - 0055 South Miami Florida Not Yet Recruiting
Local Institution - 0081 New York New York Not Yet Recruiting
Local Institution - 0079 New York New York Not Yet Recruiting
Local Institution - 0066 Portland Oregon Not Yet Recruiting
Local Institution - 0071 Philadelphia Pennsylvania Not Yet Recruiting
Local Institution - 0051 DeSoto Texas Withdrawn
Local Institution - 0048 Merksem Flanders Not Yet Recruiting
Local Institution - 0049 Leuven Belgium Not Yet Recruiting
Local Institution - 0083 Aparecida de Goiânia Goiás Not Yet Recruiting
Local Institution - 0033 Porto Alegre Rio Grande do Sul Not Yet Recruiting
Local Institution - 0082 Valinhos São Paulo Not Yet Recruiting
Local Institution - 0006 Beijing Beijing Municipality Not Yet Recruiting
Local Institution - 0080 Guangzhou Guangdong Not Yet Recruiting
Local Institution - 0010 Zhengzhou Henan Not Yet Recruiting
Local Institution - 0007 Nanchang Jiangxi Not Yet Recruiting
Local Institution - 0020 Shanghai Shanghai Municipality Not Yet Recruiting
Local Institution - 0001 Shanghai Shanghai Municipality Not Yet Recruiting
Local Institution - 0040 München Bavaria Not Yet Recruiting
Charité Research Organisation Berlin Germany Recruiting
Local Institution - 0021 Cologne Germany Not Yet Recruiting
Rheumazentrum Ruhrgebiet Herne Germany Recruiting
St. Josef-Stift Sendenhorst Sendenhorst Germany Recruiting
Istituto Clinico Humanitas Rozzano Milano Recruiting
Fondazione Policlinico Gemelli IRCCS Roma Italy Recruiting
Local Institution - 0053 México Mexico Not Yet Recruiting
Local Institution - 0023 Józefów Masovian Voivodeship Not Yet Recruiting
CHUAC-Complejo Hospitalario Universitario A Coruña A Coruña A Coruña [La Coruña] Recruiting
Hospital Universitario Reina Sofia Córdoba Spain Recruiting
Universitaetsspital Bern - Inselspital Bern Switzerland Recruiting
Hôpitaux Universitaire de Genève Geneva Switzerland Recruiting
Local Institution - 0060 Ivano-Frankivsk Ivano-Frankivsk Oblast Not Yet Recruiting
Local Institution - 0063 Poltava Poltava Oblast Not Yet Recruiting
Local Institution - 0064 Kyiv Ukraine Not Yet Recruiting
Local Institution - 0061 Ternopil Ukraine Not Yet Recruiting

More Bristol-Myers Squibb trials in the USA

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies Recruiting
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants Starting soon
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) Recruiting
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Active, not recruiting

Other trials for the same condition

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) Active, not recruiting
INFINITY™ With ADAPTIS™ Technology Study Active, not recruiting
R-2487 in Patients With Rheumatoid Arthritis Recruiting
IMPACT - AndHealth Autoimmune Research Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07412704 on ClinicalTrials.gov ↗ ← All trials in the USA